Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature

Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature

In order to study alternatives at the tissue biopsy to study EGFR status in NSCLC patients, we evaluated three different liquid biopsy platforms (plasma, urine and exhaled breath condensate, EBC). We also reviewed the literature of the cfDNA biological sources other than plasma and compared our resu...

Full description

Bibliographic Details
Main Authors: Michela Verzè, Roberta Minari, Letizia Gnetti, Paola Bordi, Alessandro Leonetti, Agnese Cosenza, Leonarda Ferri, Maria Majori, Massimo De Filippo, Sebastiano Buti, Donatello Gasparro, Rita Nizzoli, Cinzia Azzoni, Lorena Bottarelli, Anna Squadrilli, Paola Mozzoni, Marcello Tiseo
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Cancers
Subjects:
non-small cell lung cancer
EGFR-tyrosine kinase inhibitors
liquid biopsy
resistance mechanisms
Online Access:https://www.mdpi.com/2072-6694/13/21/5403

Internet

https://www.mdpi.com/2072-6694/13/21/5403

Similar Items